Compare Boston Scientific Corporation (BSX) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Gold Fields Limited — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while Gold Fields Limited trades at $32.48 (market cap $29.97B). The key difference: Boston Scientific Corporation is far larger — about 2.2× Gold Fields Limited's market cap, and Gold Fields Limited pays a 6.96% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | GFI | |
|---|---|---|
Market Cap | $66.37B | $29.97B |
Sector | Health | Basic Materials |
52-Week High | $108.14 | $61.52 |
52-Week Low | $42.63 | $23.95 |
Enterprise Value | $75.94B | $31.41B |
Dividend Yield | — | 6.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Gold Fields (GFI) trades at $33.53, down 1.79% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals with a P/E of 8.51, net income margin of 40.76%, and robust ROE of 52.33%. Recent earnings were mixed, with a Q1 2025 beat but subsequent misses. Cash flow improved significantly in 2025, and revenue growth accelerated to $8.8B. Analyst consensus is a Buy with a $52.75 price target, though recent news highlights operational cost pressures.
The outlook for GFI is positive based on valuation and profitability, but near-term risks include cost inflation and gold price volatility. The stock offers value with upside to analyst targets, supported by strong cash generation and a shareholder-friendly dividend policy. Key risks are execution at mines and macroeconomic factors affecting gold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
